SYS-CON MEDIA Authors: Jim Kaskade, Yeshim Deniz, Elizabeth White, Greg Ness, Sean Houghton

News Feed Item

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Summary

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug's performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.

Scope

- The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
- A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
- In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
- Overview of how innovation products are contributing to the market for SLE therapeutics
- Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
- The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
- First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets

Reasons to buy

The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to -
- Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
- Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
- Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
- Identify the list of first-in-class programs that are potentially open to deal-making opportunities
- Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 The Case for Innovation in Systemic Lupus Erythematosus 7
2.2 Growing Opportunities for Biologic Products 7
2.3 Diversification of Molecular Targets 7
2.4 Innovative First-in-Class Product Developments Remain Attractive 8
2.5 Changes in the Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 8
2.6 Sustained Innovation 8
3 Systemic Lupus Erythematosus 9
3.1 Disease Overview 9
3.2 Epidemiology 9
3.3 Disease Pathophysiology 10
3.4 Disease Symptoms 10
3.5 Environmental and Genetic Predisposition 11
3.6 Diagnosis 11
3.7 Disease Severity Assessments 12
3.7.1 PGA 12
3.7.2 SLEDAI 12

3.7.3 BILAG 13
3.7.4 SRI 13
3.8 Lupus Nephritis 13
3.9 Pharmacotherapy Algorithm 14
4 Clinical and Commercial Landscape 16
4.1 Corticosteroids 16
4.2 Antimalarials 16
4.3 Cytotoxic Chemotherapy 16
4.4 Biologics 17
4.4.1 Benlysta (belimumab) 17
4.5 Comparative Strengths and Weaknesses of Traditional Therapeutics 19
4.5.1 Corticosteroids vs Cytotoxic Therapeutics 19
4.5.2 Comparison of Immunosuppressants: Cyclosporine vs Azathioprine or Cyclophosphamide 21
4.5.3 Cyclophosphamide vs Azathioprine 23
4.5.4 Cyclophosphamide vs Mycophenolate Mofetil 23
4.5.5 Mycophenolate Mofetil vs Azathioprine 23
4.5.6 Biologics vs Immunosuppressants 25
4.6 Current Unmet Needs in the Systemic Lupus Erythematosus Market 27
5 Assessment of Pipeline Product Innovation 28
5.1 Overview of Pipeline Products for Systemic Lupus Erythematosus 28

5.2 Frequently Targeted Molecular Target Families 29
5.3 Comparative Distribution of Programs between the Systemic Lupus Erythematosus Market and Pipeline by Therapeutic Target Family 30
5.4 Comparative Efficacy and Safety of Pipeline Programs 31
5.5 Comparative Distribution of Programs with First-in-Class and Established Targets 33
5.6 Pipeline Programs Targeting Established Molecular Targets 35
5.7 First-in-class Pipeline Programs with Novel Molecular Targets 37
6 First-in-Class Target and Pipeline Program Evaluation 39
6.1 Cytokines and Receptors 39
6.1.1 Pipeline Programs Targeting IFN-? 39
6.1.2 Pipeline Programs Targeting CD74 43
6.1.3 Pipeline Programs Targeting B7 Related Protein 44
6.1.4 Pipeline Programs Targeting IL-21 46
6.1.5 Pipeline Programs Targeting IL-17 49
6.1.6 Pipeline Programs Targeting High Mobility Protein Box 1 51
6.1.7 Pipeline Programs Targeting APRIL 53
6.2 B and T Cell Antigens 55
6.2.1 Pipeline Programs Targeting CD4 55
6.2.2 Pipeline Programs Targeting CD40L 57
6.2.3 Pipeline Programs which Target Fc?R2b (CD32b) 60
6.2.4 Pipeline Programs which Target CD19 62
6.2.5 Pipeline Programs which Target CD22 64
6.3 Intracellular Kinase 67

6.3.1 Pipeline Programs which Target Spleen Tyrosine Kinase 67
6.4 Others 70
6.4.1 Pipeline Programs which Target Immunoproteasome subunit 7 (IMP7) 70
6.4.2 Pipeline Programs which Target ILT-7 71
7 Conclusions 72
8 Deals and Strategic Consolidations 74
8.1 Licensing Agreements 74
8.2 Co-development Deals 76
8.2.1 First-in-Class Developmental Programs Not Involved in Co-development Deals or Licensing Deals 78
9 Appendix 79
9.1 References 79
9.2 Abbreviations 88
9.3 Methodology 89
9.4 Contact Us 89
9.5 Disclaimer 89

List of Tables

Table 1: SLEDAI Index 12
Table 2: Classification of Lupus Nephritis 14
Table 3: Pipeline, Global, First-in-class Modulators of B7-Related Protein, Scientific Assessment 44
Table 4: Pipeline, Global, First-in-Class Modulators of IL-17, Scientific Assessment 49
Table 5: Pipeline, Global, First-in-class Modulators of APRIL, Scientific Assessment 53
Table 6: Pipeline, Global, First-in-class Modulators of CD4, Scientific Assessment 55
Table 7: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Scientific Assessment 60
Table 8: Pipeline, Global, First-in-Class Modulators of CD19, Scientific Assessment 62
Table 9: Pipeline, Global, First-in-Class Modulators of CD22, Scientific Assessment 65
Table 10: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Scientific Assessment 70
Table 11: Pipeline, Global, First-in-Class Modulators of Immunoproteasome Subunit 7, Pipeline Development 71
Table 12: Pipeline, Global, First-in-Class Modulators of Immunoglobulin-Like Transcript 7, Pipeline Development 71

List of Figures

Figure 1: SLE, Treatment Algorithm 14
Figure 2: Systemic Lupus Erythematosus, Global, Marketed Products 18
Figure 3: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Marketed Products 19
Figure 4: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 20
Figure 5: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 22
Figure 6: Systemic Lupus Erythematosus, Global, Marketed Products, Comparative Efficacy and Safety 24
Figure 7: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety 26
Figure 8: Systemic Lupus Erythematosus, Global Pipeline Overview 28
Figure 9: Systemic Lupus Erythematosus, Global, Pipeline and Marketed Products 30
Figure 10: Systemic Lupus Erythematosus, Global, Comparative Efficacy and Safety of Pipeline Programs Relative to Benlysta (belimumab) 32
Figure 11: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Products 34
Figure 12: Systemic Lupus Erythematosus, Global, Pipeline, Programs with Established Molecule Targets 36
Figure 13: Systemic Lupus Erythematosus, Global, Pipeline, First-in-class Programs 38
Figure 14: Pipeline, Global, First-in-Class IFN-? Inhibitors, Scientific assessment 41
Figure 15: Pipeline, Global, First-in-Class IFN-? Inhibitors, Pipeline Development 42
Figure 16: Pipeline, Global, First-in-Class CD74 Inhibitors, Pipeline Development 43
Figure 17: Pipeline, Global, First-in-Class Modulators of B7-Related Protein, Pipeline Development 45
Figure 18: Pipeline, Global, First-in-class modulators of IL-21, Scientific Assessment 47
Figure 19: Pipeline, Global, First-in-class Modulators of IL-21, Pipeline Development 48
Figure 20: Pipeline, Global, First-in-Class Modulators of IL-17 , Pipeline Development 50
Figure 21: Pipeline, Global, First-in-Class High Mobility Box Protein 1 Inhibitors, Pipeline Development 52

Figure 22: Pipeline, Global, First-in-class Modulators of APRIL, Pipeline Development 54
Figure 23: Pipeline, Global, First-in-class Modulators of CD4, Pipeline Development 56
Figure 24: Pipeline, Global, First-in-Class Modulators of CD40L, Scientific Assessment 58
Figure 25: Pipeline, Global, First-in-Class Modulators of CD40L, Pipeline Development 59
Figure 26: Pipeline, Global, First-in-Class Modulators of Fc?R2b, Pipeline Development 61
Figure 27: Pipeline, Global, First-in-Class Modulators of CD19, Pipeline Development 63
Figure 28: Pipeline, Global, First-in-Class Modulators of CD22, Pipeline Development 66
Figure 29: Pipeline, Global, First-in-Class Modulators of Spleen Tyrosine Kinase, Scientific Assessment 68
Figure 30: Pipeline, Global, First-in-Class modulators of Spleen Tyrosine Kinase, Pipeline Development 69
Figure 31: Systemic Lupus Erythematosus, Global, Licensing Agreements, 2006–2013 (October) 75
Figure 32: Systemic Lupus Erythematosus, Global, Co-development deals, 2006–2013 (October) 77
Figure 33: Systemic Lupus Erythematosus, Global, First in-Class Programs Not Involved in Co-development or Licensing Deals 78

To order this report: Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
http://www.reportlinker.com/p02003228/Frontier-Pharma-Systemic-Lupus-Erythematosus---Identifying-and-Commercializing-First-in-Class-Innovation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the ...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
Fundamentally, SDN is still mostly about network plumbing. While plumbing may be useful to tinker with, what you can do with your plumbing is far more intriguing. A rigid interpretation of SDN confines it to Layers 2 and 3, and that's reasonable. But SDN opens opportunities for novel constructions in Layers 4 to 7 that solve real operational problems in data centers. "Data center," in fact, might become anachronistic - data is everywhere, constantly on the move, seemingly always overflowing. Net...
"ElasticBox is an enterprise company that makes it very easy for developers and IT ops to collaborate to develop, build and deploy applications on any cloud - private, public or hybrid," stated Monish Sharma, VP of Customer Success at ElasticBox, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at @ThingsExpo, Robin Raymond, Chief Architect...
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to th...
What do a firewall and a fortress have in common? They are no longer strong enough to protect the valuables housed inside. Like the walls of an old fortress, the cracks in the firewall are allowing the bad guys to slip in - unannounced and unnoticed. By the time these thieves get in, the damage is already done and the network is already compromised. Intellectual property is easily slipped out the back door leaving no trace of forced entry. If we want to reign in on these cybercriminals, it's hig...
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises the IoT, you’ll see that it includes everything from cloud computing, Big Data analytics, “Things,” Web communication, applications, network, storage, etc. It is essentially including everything connected online from ha...
SYS-CON Media announced that Centrify, a provider of unified identity management across cloud, mobile and data center environments that delivers single sign-on (SSO) for users and a simplified identity infrastructure for IT, has launched an ad campaign on Cloud Computing Journal. The ads focus on security: how an organization can successfully control privilege for all of the organization’s identities to mitigate identity-related risk without slowing down the business, and how Centrify provides ...